THRD — THIRD HARMONIC BIO INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 3 SEC-registered investment managers reported holding THRD (THIRD HARMONIC BIO INC) in their latest 13F filings, with a combined reported value of $109.99K across 20.44K shares. That is +0.0% by share count (+0 shares) versus the previous quarter, while reported value moved +0.0%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of THIRD HARMONIC BIO INC (THRD) include Atlas Venture Life Science Advisors, LLC, GENERAL ATLANTIC, L.P., EcoR1 Capital, LLC, ranked by reported 13F value among the 180 institutional holders on this page.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 2 | 20.44K | $109.95K | +0.0% |
| Q2 2026 | 3 | 20.44K | $109.99K | +0.0% |
| Q1 2026 | 4 | 20.46K | $109.99K | -1.4% |
| Q4 2025 | 4 | 20.75K | $111.54K | -2.1% |
| Q3 2025 | 13 | 499.95K | $1.19M | -6.9% |
| Q2 2025 | 111 | 40.17M | $218.06M | +7.0% |
| Q1 2025 | 100 | 39.33M | $136.46M | +5.1% |
| Q4 2024 | 100 | 46.04M | $470.00M | +1.0% |
Over the 8 quarters shown, institutional share counts decreased 100% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q2 2025 (+7.0%).
Top Institutional Holders (Q3 2026) — 2 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 19.98K | $107.49K | 0.00% | Hold | |
| 458 | $2.46K | 0.00% | Hold |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 19.98K | $107.49K | 0.00% | Hold | |
| 458 | $2.46K | 0.00% | Hold | |
| 1 | $41 | 0.00% | Hold |
Q1 2026 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 19.98K | $107.49K | 0.00% | Reduce | |
| 458 | $2.46K | 0.00% | Hold | |
| 1 | $41 | 0.00% | Hold | |
| 20 | $1 | 0.00% | Hold |
Q4 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 20.27K | $109.03K | 0.00% | Reduce | |
| 458 | $2.46K | 0.00% | Hold | |
| 1 | $41 | 0.00% | Hold | |
| 20 | $1 | 0.00% | Hold |
Q3 2025 — 13 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 93.94K | $505.39K | 0.00% | Hold | |
| 86.33K | $464.43K | 0.01% | New | |
| 20.71K | $111.40K | 0.00% | Reduce | |
| 16.86K | $90.70K | 0.00% | Hold | |
| 250.00K | $7.50K | 0.00% | New | |
| 803 | $4.32K | 0.00% | Add | |
| 665 | $4.00K | 0.00% | Hold | |
| 458 | $2.46K | 0.00% | Add | |
| 196 | $1.05K | 0.00% | New | |
| 27.96K | $839 | 0.00% | Hold | |
| 2.02K | $61 | 0.00% | Hold | |
| 1 | $41 | 0.00% | Hold | |
| 20 | $1 | 0.00% | Hold |
Q2 2025 — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 10.40M | $56.48M | 8.53% | Hold | |
| 5.78M | $31.38M | 0.82% | Hold | |
| 3.82M | $20.77M | 15.71% | Hold | |
| 2.94M | $15.96M | 0.71% | Hold | |
| 1.92M | $10.40M | 1.19% | Reduce | |
| 1.73M | $9.38M | 0.00% | Add | |
| 1.30M | $7.05M | 0.00% | Add | |
| 1.25M | $6.79M | 0.02% | Add | |
| 1.25M | $6.79M | 0.01% | Add | |
| 929.73K | $5.05M | 0.26% | Hold | |
| 770.80K | $4.19M | 0.04% | Add | |
| 622.87K | $3.38M | 0.56% | Add | |
| 577.19K | $3.13M | 0.00% | Add | |
| 503.84K | $2.74M | 0.36% | New | |
| 468.99K | $2.55M | 0.00% | Add | |
| 426.90K | $2.32M | 0.02% | New | |
| 370.00K | $2.01M | 0.31% | Hold | |
| 334.48K | $1.82M | 0.45% | New | |
| 293.63K | $1.59M | 0.60% | New | |
| 290.00K | $1.57M | 1.96% | Add | |
| 272.47K | $1.48M | 0.00% | Reduce | |
| 251.68K | $1.37M | 0.21% | New | |
| 239.39K | $1.30M | 0.01% | New | |
| 225.50K | $1.22M | 4.68% | Add | |
| 221.09K | $1.20M | 0.00% | Add |
New Positions (Q2 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
- SBI Securities Co., Ltd. sold 20 sh · $1
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | 19.98K | 19.98K | 19.98K | 20.27K | 20.71K | 33.67K | 28.17K | 28.92K | 28.72K | 28.60K | 20.66K | 19.77K | 18.63K | — | — | — | — |
| GAMMA Investing LLC | 458 | 458 | 458 | 458 | 458 | 105 | — | 97 | 120 | 113 | 97 | 77 | — | — | — | — | — |
| Atlas Venture Life Science Advisors, LLC | — | — | — | — | — | 10.40M | 10.40M | 10.40M | 10.91M | 10.91M | 10.91M | 10.91M | 10.91M | — | — | — | — |
| ORBIMED ADVISORS LLC | — | — | — | — | — | 5.78M | 5.78M | 5.78M | 5.78M | 5.78M | 5.78M | 5.78M | 5.78M | — | — | — | — |
| BVF INC/IL | — | — | — | — | — | — | 2.37M | 2.37M | 4.37M | 4.37M | 4.37M | 4.37M | 4.37M | — | — | — | — |
| EcoR1 Capital, LLC | — | — | — | — | — | — | — | 3.18M | 3.18M | 3.18M | 3.18M | 3.18M | 2.98M | — | — | — | — |
| GENERAL ATLANTIC, L.P. | — | — | — | — | — | — | — | 3.37M | 2.96M | 2.96M | 2.96M | 2.96M | 2.96M | — | — | — | — |
| T. Rowe Price Investment Management, Inc. | — | — | — | — | — | — | — | 2.93M | 2.83M | 1.35M | — | — | — | — | — | — | — |
| TCG Crossover Management, LLC | — | — | — | — | — | 1.92M | 2.51M | 2.51M | 2.42M | — | — | — | — | — | — | — | — |
| RA CAPITAL MANAGEMENT, L.P. | — | — | — | — | — | — | — | 960.62K | 1.28M | 2.03M | 2.03M | 2.03M | 961.86K | — | — | — | — |
| Fidelity Management & Research (FMR) | — | — | — | — | — | 4.41K | 1.07K | 2.54M | 307.99K | 3.74K | 3.77K | 3.72K | 3.44K | 2.75K | 981 | 109 | — |
| BML Capital Management, LLC | — | — | — | — | — | 3.82M | 3.82M | — | — | — | — | — | — | — | — | — | — |
| Boxer Capital Management, LLC | — | — | — | — | — | — | — | 2.00M | — | — | — | — | — | — | — | — | — |
| Commodore Capital LP | — | — | — | — | — | — | — | 237.70K | 1.36M | 1.55M | 1.25M | 706.71K | 1.70M | — | — | — | — |
| BlackRock Inc | — | — | — | — | — | 1.73M | 1.48M | 1.48M | 1.46M | — | — | — | — | — | — | — | — |
| Nantahala Capital Management, LLC | — | — | — | — | — | 2.94M | 2.94M | 501.00K | — | — | — | — | — | — | — | — | — |
| BRAIDWELL LP | — | — | — | — | — | — | — | — | — | — | — | 1.32M | 1.65M | — | — | — | — |
| Vanguard Group | — | — | — | — | — | 1.30M | 1.16M | 1.03M | 891.65K | 873.80K | 851.39K | 839.88K | 773.46K | 769.84K | 747.95K | 696.37K | 100.00K |
| TANG CAPITAL MANAGEMENT LLC | — | — | — | — | — | 929.73K | 929.73K | 150.00K | — | — | — | — | 1.80M | — | — | — | — |
| JPMorgan Chase & Co | — | — | — | — | — | 95.54K | 264.42K | 36.15K | 13.41K | 13.44K | 442.14K | 1.01M | 12.96K | 15.52K | 61 | 18.88K | — |
FAQ
Which funds hold THRD?
As of 2026-Q2, 3 institutional funds reported holding THRD (THIRD HARMONIC BIO INC) in SEC 13F filings, with a combined reported value of $109.99K.
How many shares of THRD do institutions own?
13F filers reported 20.44K shares of THRD, worth $109.99K in aggregate at the end of 2026-Q2.
Is institutional ownership of THRD rising or falling?
Share counts moved +0.0% versus the prior quarter — accumulation.
Who are the top institutional holders of THRD?
The largest 13F holders are Atlas Venture Life Science Advisors, LLC, GENERAL ATLANTIC, L.P., EcoR1 Capital, LLC, ORBIMED ADVISORS LLC, T. Rowe Price Investment Management, Inc.; the top 25 are ranked at the top of this page.
Who are the major shareholders of THIRD HARMONIC BIO INC?
The major shareholders of THIRD HARMONIC BIO INC (THRD) by reported 13F value are Atlas Venture Life Science Advisors, LLC, GENERAL ATLANTIC, L.P., EcoR1 Capital, LLC, ORBIMED ADVISORS LLC, T. Rowe Price Investment Management, Inc., among 180 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.